These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 36960814)
1. Efficacy and safety of lemborexant as an alternative drug for patients with insomnia taking gamma-aminobutyric acid-benzodiazepine receptor agonists or suvorexant. Okino K; Suzuki H; Tomioka H; Sanada K; Kawai K; Iwanami A; Inamoto A Hum Psychopharmacol; 2023 May; 38(3):e2868. PubMed ID: 36960814 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Transitioning to Lemborexant from Z-drug, Suvorexant, and Ramelteon in Japanese Insomnia Patients: An Open-label, Multicenter Study. Ozone M; Hirota S; Ariyoshi Y; Hayashida K; Ikegami A; Habukawa M; Ohshima H; Harada D; Hiejima H; Kotorii N; Murotani K; Taninaga T; Uchimura N Adv Ther; 2024 Apr; 41(4):1728-1745. PubMed ID: 38460107 [TBL] [Abstract][Full Text] [Related]
3. A retrospective clinical practice study comparing the usefulness of dual-orexin receptor antagonists and a melatonin receptor agonist in patients switching from long-term benzodiazepine receptor agonists. Tachibana M; Kanahara N; Oda Y; Hasegawa T; Kimura A; Iyo M J Clin Sleep Med; 2024 Apr; 20(4):603-613. PubMed ID: 38063235 [TBL] [Abstract][Full Text] [Related]
4. Evidence-based insomnia treatment strategy using novel orexin antagonists: A review. Kishi T; Nishida M; Koebis M; Taninaga T; Muramoto K; Kubota N; Moline M; Sakuma K; Okuya M; Nomura I; Iwata N Neuropsychopharmacol Rep; 2021 Dec; 41(4):450-458. PubMed ID: 34553844 [TBL] [Abstract][Full Text] [Related]
5. Lemborexant, an orexin receptor antagonist sedative-hypnotic: Is it useful for insomnia in psychiatric disorders? Keks NA; Hope J Australas Psychiatry; 2022 Aug; 30(4):530-532. PubMed ID: 35491942 [TBL] [Abstract][Full Text] [Related]
6. The effect of lemborexant on insomnia in patients with psychiatric disorders: Detailed evaluation using the Athens Insomnia Scale. Murayama T; Ito Y; Narita K; Ishida T; Hinotsu S; Fujita M PCN Rep; 2024 Mar; 3(1):e165. PubMed ID: 38868465 [TBL] [Abstract][Full Text] [Related]
7. Assessment of Switching to Suvorexant versus the Use of Add-on Suvorexant in Combination with Benzodiazepine Receptor Agonists in Insomnia Patients: A Retrospective Study. Hatano M; Kamei H; Inagaki R; Matsuzaki H; Hanya M; Yamada S; Iwata N Clin Psychopharmacol Neurosci; 2018 May; 16(2):184-189. PubMed ID: 29739132 [TBL] [Abstract][Full Text] [Related]
8. Switching to lemborexant for the management of insomnia in mental disorders: the SLIM study. Horikoshi S; Miura I; Suzuki Y; Kobayashi Y; Hirata Y; Goto M; Ichinose M; Yamamoto S; Kanno-Nozaki K; Watanabe K; Yabe H J Clin Sleep Med; 2023 Oct; 19(10):1753-1758. PubMed ID: 37243798 [TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy and safety of suvorexant and lemborexant for insomnia treatment. Hayashi T; Yamanashi T; Iwata M PCN Rep; 2023 Mar; 2(1):e85. PubMed ID: 38868407 [TBL] [Abstract][Full Text] [Related]
10. Dual orexin receptor antagonists for treatment of insomnia: A systematic review and meta-analysis on randomized, double-blind, placebo-controlled trials of suvorexant and lemborexant. Khazaie H; Sadeghi M; Khazaie S; Hirshkowitz M; Sharafkhaneh A Front Psychiatry; 2022; 13():1070522. PubMed ID: 36578296 [TBL] [Abstract][Full Text] [Related]
11. Insomnia in Elderly Patients: Recommendations for Pharmacological Management. Abad VC; Guilleminault C Drugs Aging; 2018 Sep; 35(9):791-817. PubMed ID: 30058034 [TBL] [Abstract][Full Text] [Related]
12. In vitro characterization of benzodiazepine receptor agonists, antagonists, inverse agonists and agonist/antagonists. Wood PL; Loo P; Braunwalder A; Yokoyama N; Cheney DL J Pharmacol Exp Ther; 1984 Dec; 231(3):572-6. PubMed ID: 6094792 [TBL] [Abstract][Full Text] [Related]
13. Characteristics of patients who were able to switch from benzodiazepine hypnotics to lemborexant. Suzuki H; Hibino H SAGE Open Med; 2021; 9():20503121211037903. PubMed ID: 34394934 [TBL] [Abstract][Full Text] [Related]
14. Effectiveness of suvorexant versus benzodiazepine receptor agonist sleep drugs in reducing the risk of hip fracture: Findings from a regional population-based cohort study. Yoshioka R; Yamamoto S; Nakatani E PLoS One; 2023; 18(4):e0284726. PubMed ID: 37093840 [TBL] [Abstract][Full Text] [Related]
15. [Novel insomnia drugs, including drugs currently under development]. Inada K Nihon Rinsho; 2009 Aug; 67(8):1590-4. PubMed ID: 19768946 [TBL] [Abstract][Full Text] [Related]
16. A Comprehensive Review of Lemborexant to Treat Insomnia. Fuller MC; Carlson SF; Grant C; Berry V; Ivancich M; Cornett EM; Kaye AM; Viswanath O; Urits I; Shekoohi S; Kaye AD Psychopharmacol Bull; 2024 Mar; 54(1):43-64. PubMed ID: 38449475 [TBL] [Abstract][Full Text] [Related]
17. Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2. Kärppä M; Yardley J; Pinner K; Filippov G; Zammit G; Moline M; Perdomo C; Inoue Y; Ishikawa K; Kubota N Sleep; 2020 Sep; 43(9):. PubMed ID: 32585700 [TBL] [Abstract][Full Text] [Related]
18. [Preclinical and clinical efficacy of orexin receptor antagonist Lemborexant (Dayvigo Koebisu M; Koyama N; Nishida M; Muramoto K Nihon Yakurigaku Zasshi; 2021; 156(2):114-119. PubMed ID: 33642529 [TBL] [Abstract][Full Text] [Related]
19. The benzodiazepine diazepam potentiates responses of α1β2γ2L γ-aminobutyric acid type A receptors activated by either γ-aminobutyric acid or allosteric agonists. Li P; Eaton MM; Steinbach JH; Akk G Anesthesiology; 2013 Jun; 118(6):1417-25. PubMed ID: 23407108 [TBL] [Abstract][Full Text] [Related]
20. Effectiveness of change from suvorexant to lemborexant drug in the treatment of sleep disorders. Okino K; Suzuki H; Kondo S; Tomioka H; Tokumasu T; Yamada H; Iwanami A; Inamoto A Psychogeriatrics; 2022 Sep; 22(5):595-604. PubMed ID: 35689366 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]